SubsidieMeestersScalable and Eco-friendly Bioproduction
Core Biogenesis aims to become the European leader in plant-based biomanufacturing by 2025, using a novel process to significantly enhance yield and reduce costs for producing pharmaceutical proteins.
Projectdetails
Introduction
Core Biogenesis uses plant-based expression systems for the very large-scale and high-quality bioproduction of pharmaceutical-grade recombinant proteins. The latter are used as growth factors (GF) in synthetic cell culture media for clinical and commercial scale biomanufacturing of cell therapy.
Innovation in Bioprocess
The company has developed a novel advanced proprietary bioprocess integrating breakthrough innovations overcoming major technical issues of plant systems. This bioprocess offers:
- A 25-fold yield increase
- A 10-fold cost reduction
Biomanufacturing Platform
Its biomanufacturing platform will enable Core Biogenesis to fully exploit the great potential of plants for large and scalable production capacity. Plants are well known to be the most promising system for production upscaling.
Future Ambition
Core Biogenesis’s ambition is to position itself as the European leader in plant-based biomanufacturing by 2025.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 1.153.390 |
| Totale projectbegroting | € 1.647.700 |
Tijdlijn
| Startdatum | 1-1-2023 |
| Einddatum | 31-12-2024 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- CORE BIOGENESISpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
A new cardioprotective drug for acute treatment of myocardial infarctionResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Clear, scalable and scientific framework to measure terrestrial biodiversity3Bee leverages IoT, wildlife monitoring, and satellite data to measure and regenerate biodiversity, generating certified Biodiversity Credits for corporations to enhance ESG reporting and brand value. | EIC Accelerator | € 2.252.714 | 2024 | Details |
Novel and Scalable microbial products for REgenerative agricultureN-Spire aims to revolutionize agriculture by creating a sustainable bioactive fertilizer through innovative manufacturing techniques, enhancing soil health and reducing chemical dependency. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Quantum-based Randomness Processing Units (RPUs) for High-Performance Computation and Data SecurityQuside's Randomness Processing Unit (RPU) accelerates stochastic HPC and PQ cryptography by optimizing random workloads, enhancing efficiency and performance across various sectors. | EIC Accelerator | € 2.499.999 | 2024 | Details |
A new cardioprotective drug for acute treatment of myocardial infarction
ResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies.
Clear, scalable and scientific framework to measure terrestrial biodiversity
3Bee leverages IoT, wildlife monitoring, and satellite data to measure and regenerate biodiversity, generating certified Biodiversity Credits for corporations to enhance ESG reporting and brand value.
Novel and Scalable microbial products for REgenerative agriculture
N-Spire aims to revolutionize agriculture by creating a sustainable bioactive fertilizer through innovative manufacturing techniques, enhancing soil health and reducing chemical dependency.
Quantum-based Randomness Processing Units (RPUs) for High-Performance Computation and Data Security
Quside's Randomness Processing Unit (RPU) accelerates stochastic HPC and PQ cryptography by optimizing random workloads, enhancing efficiency and performance across various sectors.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Translating a new metabolic engineering strategy to industrial biotech applicationsThe TRANSMETECH project aims to translate the StrainBooster metabolic engineering strategy into industrial applications, enhancing bioprocess efficiency for sustainable chemical production. | ERC POC | € 150.000 | 2023 | Details |
Genetisch gemodificeerde micro-organismen op een bio-based dieetEV Biotech onderzoekt de haalbaarheid van genetisch gemodificeerde micro-organismen die zetmeel kunnen afbreken voor duurzame biomolecuulproductie, ter vervanging van dure glucose. | MIT Haalbaarheid | € 20.000 | 2023 | Details |
BioMaxBioMax ontwikkelt een snelle analytische methode voor biopesticides en test nieuwe celvrije schimmelwerende middelen, wat tijd en kosten bespaart in de landbouw. | MIT R&D Samenwerking | € 108.570 | 2023 | Details |
Haalbaarheidsstudie voor een groeifactorproductiebedrijfHet project richt zich op het verlagen van de kosten van groeifactoren voor kweekvleesproductie door deze op grotere schaal te produceren, ter ondersteuning van de eiwittransitie. | MIT Haalbaarheid | € 20.000 | 2022 | Details |
Translating a new metabolic engineering strategy to industrial biotech applications
The TRANSMETECH project aims to translate the StrainBooster metabolic engineering strategy into industrial applications, enhancing bioprocess efficiency for sustainable chemical production.
Genetisch gemodificeerde micro-organismen op een bio-based dieet
EV Biotech onderzoekt de haalbaarheid van genetisch gemodificeerde micro-organismen die zetmeel kunnen afbreken voor duurzame biomolecuulproductie, ter vervanging van dure glucose.
BioMax
BioMax ontwikkelt een snelle analytische methode voor biopesticides en test nieuwe celvrije schimmelwerende middelen, wat tijd en kosten bespaart in de landbouw.
Haalbaarheidsstudie voor een groeifactorproductiebedrijf
Het project richt zich op het verlagen van de kosten van groeifactoren voor kweekvleesproductie door deze op grotere schaal te produceren, ter ondersteuning van de eiwittransitie.